Cerevance to present data of KCNK13 inhibitor at Alzheimer’s Association International Conference 2025

Overview

Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, announced upcoming presentations at the Alzheimer's Association International Conference (AAIC) 2025, is being held in Toronto from July 27 to 31, 2025.

Phase I trial outcome data

Data from the phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally well-tolerated. Proprietary NETSseq platform explores the key potential role of astrocytes in Alzheimer’s disease.

Poster presentations

Details of the poster presentations at AAIC 2025 are as follows:

• Title: CVN293, an investigational inhibitor of KCNK13 targeting NLRP3-mediated neuroinflammation in Neurodegenerative Disease: A phase 1 clinical study to investigate the safety, tolerability, and Pharmacokinetics.
• Session date/time: on July 28, 2025, 7:30 a.m.– 4:15 p.m. ET
• Title: NETSseq unveils deep molecular insights into astrocyte function in Alzheimer’s disease in the human brain.

Session date/time: on July 30, 2025, 7:30 a.m.– 4:15 p.m. ET

About Nuclear Enriched Transcript Sort sequencing (NETSseq)

• The proprietary platform, Nuclear Enriched Transcript Sort sequencing (NETSseq), enables the identification of subtle molecular changes that drive disease progression. 
• By analyzing brain tissue from a diverse pool of over 20,000 donors, ranging in age from 8 to 104, and including both healthy individuals and those with various central nervous system disorders, NETSseq allows us to identify targets that are expressed at very low levels, are present in rare cell types, or change over time as a disease progresses. 
• This transformative tool provides deep insights into the molecular drivers of disease within specific cell populations, expanding our understanding and treatment of neurodegenerative diseases. 
• It enables us to pursue therapies that directly address underlying disease mechanisms. 
• Our platform has been instrumental in the development of our investigational assets, forming a cornerstone of our innovative approach to CNS drug discovery.

About the drug: CVN293

• CVN293 is an investigational, highly selective oral inhibitor of the potassium two pore domain channel subfamily K member 13 (KCNK13). 
• By selectively inhibiting KCNK13, a potentially novel regulator of NLRP3 inflammasome activation, CVN293 aims to reduce neuroinflammation and slow disease progression in a variety of neurodegenerative disorders. 
• This mechanism may provide a disease-modifying approach for challenging CNS disorders. Additionally, modulation of KCNK13 may have therapeutic benefit in obesity. 
• KCNK13 was identified by Cerevance’s proprietary NETSseq platform.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!